

September 23, 2022

**National Stock Exchange of India Ltd.**  
**“Exchange Plaza”**  
**Bandra-Kurla Complex,**  
**Bandra (E), Mumbai-400 051**  
**Stock Code: ORCHIDPHAR**

**BSE Limited**  
**25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers,**  
**Dalal Street,**  
**Mumbai-400001**  
**Stock Code: 524372**

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”) - Scheme of Amalgamation and Arrangement.**

Dear Sir/Madam,

The Company had filed an application jointly with Dhanuka Laboratories Limited on April 27, 2022 before National Company Law Tribunal (NCLT), Chennai Bench for sanction of the proposed Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited (Amalgamating Company/ Transferor Company) and Orchid Pharma Limited (Amalgamated Company/ Transferee Company) and their respective shareholders and creditors. NCLT Chennai listed the matter for hearing on July 27, 2022 pursuant to which the first motion order in our matter was duly reserved.

Our matter was next listed on September 09, 2022 for pronouncement pursuant to which NCLT, Chennai dismissed our application. While the pronouncement took place on September 09, 2022, please note that the order was received by us only recently on September 20, 2022.

The company shall be complying with the directions given by NCLT, Chennai in the above stated order. A copy of the order as received by us is attached herewith for your perusal and records.

We request you to take the above on record.

Thanking You,

For and on behalf of,  
**Orchid Pharma Limited**

**Manish Dhanuka**  
**Managing Director**  
**DIN: 00238798**